A study of more than 600,000 U.S. military veterans, published in the BMJ on March 4, found that patients prescribed GLP-1 receptor agonist drugs — the class that includes semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro) — had significantly lower rates of developing new substance use disorders across every major category: alcohol, opioids, nicotine, cocaine, and cannabis [1]. The study, led by researchers at Washington University School of Medicine in St. Louis, followed patients for up to three years and controlled for obesity, diabetes status, and prior addiction history.

The findings are not subtle. Veterans on GLP-1 drugs showed a 40 percent reduction in the risk of alcohol use disorder, a 33 percent reduction for opioid use disorder, and a 24 percent reduction for nicotine dependence, compared to matched controls on other diabetes medications [2]. The effect was consistent across demographic groups and held regardless of whether patients were prescribed the drugs for diabetes management or weight loss. The researchers described the results as "the strongest population-level evidence to date" that GLP-1 drugs have neurological effects beyond appetite suppression [1].

The biological mechanism is plausible but unproven at this scale. GLP-1 receptors are found not only in the pancreas and gut but throughout the brain, including in the nucleus accumbens and ventral tegmental area — the same reward circuitry that addiction hijacks [3]. Animal studies dating to 2019 showed that GLP-1 agonists reduced alcohol consumption in rats. The veteran study is the first to demonstrate the association in a large human population.

The New Yorker's February cover story asked the question directly: "Can Ozempic Cure Addiction?" [4]. The piece profiled patients who reported that their cravings for alcohol, cigarettes, and even gambling diminished or disappeared within weeks of starting semaglutide. Researchers quoted in the article cautioned that anecdotal reports and epidemiological associations are not the same as a randomized controlled trial. No such trial has been completed. Several are underway, including a National Institute on Alcohol Abuse and Alcoholism study expected to report results in 2028.

The pricing question shadows everything. Ozempic's list price exceeds $900 per month in the United States. Wegovy, the weight-loss formulation, costs approximately $1,350 per month. Insurance coverage is inconsistent. Medicare covers GLP-1 drugs for diabetes but, until the Treat and Reduce Obesity Act passed the House last month, did not cover them for weight management [5]. If the drugs also prevent addiction, the coverage gap becomes a moral question: should a veteran who cannot afford Ozempic be denied a medication that might keep him off opioids?

NPR reported that the study has already influenced prescribing patterns at several VA medical centers, where physicians are considering GLP-1 drugs as part of integrated treatment plans for patients with comorbid diabetes and substance use disorders [6]. The VA's formulary committee is reviewing whether to expand GLP-1 access specifically for patients with addiction risk factors.

On X, the response bifurcated cleanly. The science-curious marveled at a drug class that started as a diabetes treatment, became a weight-loss phenomenon, and now appears to modulate the brain's reward system. The health-policy crowd pointed to the price tag and asked who, exactly, is going to pay for 600,000 veterans to take a $900-per-month medication. The answer, as with most things in American health care, is: it depends on your insurance.

The study does not prove causation. It proves association in a very large, very well-documented population. The distance between association and causation is a randomized trial and several years of follow-up. But the direction is consistent, the effect size is large, and the drug class is already prescribed to millions of Americans. If GLP-1 drugs do prevent addiction, the implications extend far beyond weight loss — and the pricing debate becomes the most consequential health policy argument of the decade.

-- Nora Whitfield, Chicago